

. PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

			tion Act of 1995, no persons a	Complete if Known		
Substitute	for form 1449A/PTO			Application Number	10/030,452	
	DAAATION	DIS	CLOSURE	Filing Date	January 10, 2002	
INFO	HMAHON	V AI	DDI ICANT	First Named Inventor	Masayuki YABUTA et al.	
STATEMENT BY APPLICANT				Group Art Unit	1646	
(use as many sheets as necessary)				Examiner Name	To Be Assigned	
	(use as many sheets de literary)			Attorney Docket Number	58777.000008	
Sheet	11.	1 01 2			<u> </u>	

			U.S. PATENT DOCUM	MENTS		
Examiner	u.S. Patent Document Cite Kind Code ²		Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials *	No.1	Number (if known)		01/22/91		
	U1	4,987,070	Magota et al.	02/04/97		
	U2	5,599,690	Fenton et al.	04/22/97		
	U3	5,622,845	Brunner et al.	12/16/97		
	U4	5,698,418	Brunner et al.	12 10/9/		
<u>-</u>	+					
	+	 				
	+			ļ		
			·	ļ	-	
		 		<u></u>		
						
						
				ļ		
					<u> </u>	
						
						
		 				
						
						
- :-				•		

				FOREIGI	N PATENT DOCU	MENIS	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	For Office ³	eign Patent Doc Number ⁴	wment Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Тв
	F1 F2 F3 F4 F5 F6	JP JP EP EP JP	61119189 62044198 0683233 0164273 687788 2879063	A2 A2	Mizumoto et al Hanada Shinobu et al Matsuo et al	06/06/86 02/26/87 11/22/95 12/11/85 1/13/89 6/27/91		

Examiner		Date Considered	* *	· .
Signature	0			in conformance

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments of the Chief Information Officer, U.S. Patent and Trademark Comments of the Chief Information Officer, U.S. Patent and Trademark Comments of the Chief Information Officer, U.S. Patent and Trademark Comments of the Chief Information Officer, U.S. Patent Comments of the Chief Information Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 1993, 10 persons at	Complete if Known		
Substitute for form 1449A/PTO	Application Number	10/030,452	
INFORMATION DISCLOSURE	Filing Date	January 10, 2002	
STATEMENT BY APPLICANT	First Named Inventor	Masayuki YABUTA et al	
STATEMENT BY AFFEIGANT	Group Art Unit	1646	
t at an accessory)	Examiner Name	To Be Assigned	
(use as many sheets as necessary)	Attorney Docket Number	58777.000008	
Sheet 2 of 2	Attento, Daniel		

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), publisher, city and/or country where published.	T²					
	TSAI, Larry B. et al., "Control of Misincorporation of <i>De Novo</i> Synthesized Norleucine into Hecombinant TSAI, Larry B. et al., "Control of Misincorporation of <i>De Novo</i> Synthesized Norleucine into Hecombinant TSAI, Larry B. et al., "Control of Misincorporation of <i>De Novo</i> Synthesized Norleucine into Hecombinant TSAI, Larry B. et al., "Control of Misincorporation of <i>De Novo</i> Synthesized Norleucine into Hecombinant TSAI, Larry B. et al., "Control of Misincorporation of <i>De Novo</i> Synthesized Norleucine into Hecombinant TSAI, Larry B. et al., "Control of Misincorporation of <i>De Novo</i> Synthesized Norleucine into Hecombinant TSAI, Larry B. et al., "Control of Misincorporation of <i>De Novo</i> Synthesized Norleucine into Hecombinant TSAI, Larry B. et al., "Control of Misincorporation of <i>De Novo</i> Synthesized Norleucine into Hecombinant TSAI, Larry B. et al., "Control of Misincorporation of <i>De Novo</i> Synthesized Norleucine into Hecombinant TSAI, Larry B. et al., "Control of Misincorporation of <i>De Novo</i> Synthesized Norleucine into Hecombinant TSAI, and "Control of Misincorporation of the Hecombinant TSAI, and						
	TO COLAN George "Biosynthesis and Incorporation into Protein of Norleucine by Escherichia coli," The Journal						
Desirions in Recombinant Human Hemoglobin							
- B4	Expressed in Eschendrilla Colli, The South State						
Polypeptide (α-nANP), Biochemical and Depty Polypeptide (α-nANP), Biochemical and Depty MASAKI, Takeharu: et al., "Studies on a New Proteolytic Enzyme from Achromobacter Lyticus M4971 II. MASAKI, Takeharu: et al., "Studies on a New Proteolytic Enzyme from Achromobacter Lyticus M4971 II. Specificity and Inhibition Studies of Achromobacter Protease 1," Biochimica et Biophysica Acta, 660:51-55 (1981).							
					Cellular and Molecular Biology, Vol. 1, pp. 164 TWIGG, Andrea J., et al., "Trans-Complementable Copy-Number Mutants of Plasmid ColE1," Nature, 283:216		
-	the sign of Cycteine " Escherichia coli and Salmonella Cellular and Molecular						
+	Biology, Vol. I, pp.514-527, Advit 1635, Value 1						
P9	VOET, Dollard et al., Decitionary						
		†					
		-					
		+					
		+-					
	No. ¹ P1 P2 P3 P4	 NO.¹ TSAI, Larry B. et al., "Control of Misincorporation of <i>De Novo</i> Synthesized Norleucine into Recombinant Interleukin-2 in <i>E. Coli</i>," <i>Biochemical and Biophysical Communications</i>, 156(2):733-739 (1988). P2 BOGOSIAN, George, "Biosynthesis and Incorporation into Protein of Norleucine by <i>Escherichia coli</i>," <i>The Journal of Biological Chemistry</i>, 264(1):531-539 (1989). P3 APOSTOL, Izydor, et al., "Incorporation of Norvaline at Leucine Positions in Recombinant Humah Hemoglobin Expressed in <i>Escherichia coli</i>," <i>The Journal of Biological Chemistry</i>, 272(46):28980-28988 (1997). P4 KANGAWA, Kenji, et al., "Purification and Complete Amino Acid Sequence of α-Human Atrial Natriuretic Polypeptide (α-hANP)," <i>Biochemical and Biophysical Research Communications</i>, 118(1):131-139 (1984). P5 MASAKI, Takeharu: et al., "Studies on a New Proteolytic Enzyme from <i>Achromobacter Lyticus</i> M4971 II. Specificity and Inhibition Studies of <i>Achromobacter</i> Protease 1," <i>Biochimica et Biophysica Acta</i>, 660:51-55 (1981). P6 NEIDHARDT, Frederick C., et al., "Chemical Composition of <i>Escherichia coli</i>," <i>Escherichia coli and Salmonella Cellular and Molecular Biology</i>, Vol. 1, pp. 13-16, ASM Press, Washington, DC (1996). P7 TWIGG, Andrea J., et al., "Trans-Complementable Copy-Number Mutants of Plasmid ColE1," <i>Nature</i>, 283:216-218 (1980). P8 KREDICH, Nicholas M., "Biosynthesis of Cysteine," <i>Escherichia coli and Salmonella Cellular and Molecular Biology</i>, Vol. 1, pp. 514-527, ASM Press, Washington, DC (1996). 					

Examiner	Date Considered	
Signature		609. Draw line through citation if not in conformance

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Comments on the Chief Information Officer, U.S. Patent and Trademark Comments on the Chief Information Officer, U.S. Patent and Trademark Comments on the Chief Information Officer, U.S. Patent and Trademark Comments on the Chief Information Officer, U.S. Patent and Trademark Comments on the Chief Information Officer, U.S. Patent and Trademark Comments on the Chief Information Officer, U.S. Patent and Trademark Comments on the Chief Information Officer, U.S. Patent and Trademark Comments on the Chief Information Officer, U.S. Patent and Trademark Comments on the Chief Information Officer, U.S. Patent Comments on the Chief Information Officer, U.S. Patent Comments on the Chief Information Officer, U.S. Patent Comments on the Chief In

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number: ² Applicant is to place a check mark here if English language Translation is attached.

PATENT

PROVISIONAL

UTILITY

Application No.: 10/030,452

DESIGN

PCT

May 10, 2002

Client/Matter No.: 58777.000008 Client: Yuasa & Hara Inventor(s): Masayuki YABUTA et al. Atty/Sec:: RMS/JTP:nej Title: METHODS FOR REDUCING THE FORMATION OF BY-

PRODUCTS IN THE PRODUCTION OF RECOMBINANT

POLYPEPTIDES

The following has been received in the U.S. Patent and Trademark
Office on the date stamped hereon:

Form PTO/SB/08A (2 pgs)

Nineteen (19) cited references

Copy of International Search Report



